Author:
Tan Wei Shen,Grajales Valentina,Contieri Roberto,Hensley Patrick,Bree Kelly,Msaouel Pavlos,Guo Charles C.,Nogueras-Gonzalez Graciela M.,Navai Neema,Dinney Colin P.,Kamat Ashish M.
Funder
National Institutes of Health
National Cancer Institute
University of Texas MD Anderson Cancer Center
Reference15 articles.
1. European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ);Babjuk;Eur Urol,2022
2. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline;Chang;J Urol,2016
3. Management of non-muscle invasive bladder cancer: a comprehensive analysis of guidelines from the United States, Europe and Asia;Tan;Cancer Treat Rev,2016
4. US Department of Health and Human Services Food and Drug Administration. BCG-unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment guidance for industry. 2018. https://www.fda.gov/media/101468/download#:∼:text=For%20the%20purposes%20of%20this,completion%20of%20adequate%20BCG%20therapy.
5. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study;Balar;Lancet Oncol,2021
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献